ABSTRACT
Polymers play important roles in the design of delivery nanocarriers for cancer therapies. Polymeric nanocarriers with anticancer drugs conjugated or encapsulated, also known as polymeric nanomedicines, form a variety of different architectures including polymer–drug conjugates, micelles, nanospheres, nanogels, vesicles, and dendrimers. This entry focuses on the current state of the preclinical and clinical investigations of polymer–drug conjugates and polymeric micelles. Recent progress achieved in some promising fields, such as site-specific protein conjugation, pH-sensitive polymer–drug conjugates, polymer nanoparticles for targeted cancer therapy, stimuli-responsive polymeric micelles, polymeric vesicles, and dendrimer-based anticancer nanomedicines, will be highlighted. This entry was originally published as “Anticancer Polymeric Nanomedicines” in the journal Polymer Reviews, Vol. 47, No. 3, 345–381.
